Millie Das

Publications

• A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Riess JW, Nagpal S, Das M, Neal JW, Kim JW, Wakelee HA. J Thorac Oncol. 2013; 8 (2): e17-8
• Angiogenesis inhibitors. Das M, Wakelee H. J Thorac Oncol. 2012; 7 (16 Suppl 5): S397-8
• ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Das M, Riess JW, Frankel P, Schwartz E, Bennis R, Hsieh HB, Liu X, Ly JC, Zhou L, Nieva JJ, Wakelee HA, Bruce RH. Lung Cancer. 2012; 77 (2): 421-6
• Angiogenesis inhibitors. Das M, Wakelee H. J Thorac Oncol. 2011; 6 (11 Suppl 4): S1801-2
• Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer. Das M, Donington JS, Murphy J, Kozak M, Eclov N, Whyte RI, Hoang CD, Zhou L, Le QT, Loo BW, Wakelee H. Clin Lung Cancer. 2011; 12 (5): 280-5
• Alternatives to surgery for early stage non-small cell lung cancer-ready for prime time? Das M, Abdelmaksoud MH, Loo BW, Kothary N. Curr Treat Options Oncol. 2010; 11 (1-2): 24-35
• Vascular disrupting agents. Das M, Wakelee H. J Thorac Oncol. 2010; 5 (12 Suppl 6): S482-3